Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Yamaguchi K; DESTINY-Gastric01 Investigators. Shitara K, et al. Among authors: kawaguchi y. N Engl J Med. 2020 Jun 18;382(25):2419-2430. doi: 10.1056/NEJMoa2004413. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469182 Clinical Trial.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J, Shimoyama T, Lee KW, Saito K, Kawaguchi Y, Kamio T, Kojima A, Sugihara M, Shitara K. Yamaguchi K, et al. Among authors: kawaguchi y. J Clin Oncol. 2023 Feb 1;41(4):816-825. doi: 10.1200/JCO.22.00575. Epub 2022 Nov 15. J Clin Oncol. 2023. PMID: 36379002 Free PMC article. Clinical Trial.
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, Lonardi S, Wainberg ZA, Ajani J, Chao J, Janjigian Y, Qin A, Singh J, Barlaskar F, Kawaguchi Y, Ku G. Van Cutsem E, et al. Among authors: kawaguchi y. Lancet Oncol. 2023 Jul;24(7):744-756. doi: 10.1016/S1470-2045(23)00215-2. Epub 2023 Jun 14. Lancet Oncol. 2023. PMID: 37329891 Clinical Trial.
Successful prism treatment for cyclic esotropia: A case report.
Nishikawa N, Kawaguchi Y, Fushitsu R, Kuroda Y, Nagaoka T. Nishikawa N, et al. Among authors: kawaguchi y. Am J Ophthalmol Case Rep. 2024 Apr 17;34:102055. doi: 10.1016/j.ajoc.2024.102055. eCollection 2024 Jun. Am J Ophthalmol Case Rep. 2024. PMID: 38707949 Free PMC article.
Re-consideration of Lymph Node Metastasis in Pancreatic Cancer Patients Following Radical Resection: A Retrospective Study.
Saito R, Kawaida H, Izumo W, Nakata Y, Amemiya H, Ozawa T, Higuchi Y, Nakayama T, Maruyama S, Takiguchi K, Shoda K, Ashizawa N, Nakayama Y, Shiraishi K, Furuya S, Akaike H, Kawaguchi Y, Ichikawa D. Saito R, et al. Among authors: kawaguchi y. Anticancer Res. 2024 May;44(5):2141-2149. doi: 10.21873/anticanres.17020. Anticancer Res. 2024. PMID: 38677773
Differences in glycemic trends due to reconstruction methods after proximal gastrectomy from the perspective of continuous glucose-monitoring.
Shoda K, Kubota T, Kawaguchi Y, Akaike H, Maruyama S, Higuchi Y, Nakayama T, Saito R, Takiguchi K, Furuya S, Shiraishi K, Amemiya H, Kawaida H, Ichikawa D. Shoda K, et al. Among authors: kawaguchi y. Surg Today. 2024 Apr 23. doi: 10.1007/s00595-024-02845-7. Online ahead of print. Surg Today. 2024. PMID: 38649530
2,676 results